Sue M Evans1, Nupur Nag1, David Roder2, Andrew Brooks3, Jeremy L Millar4, Kim L Moretti2, David Pryor5, Marketa Skala6, John J McNeil1. 1. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic., Australia. 2. Centre for Population Health Research, University of South Australia, Adelaide, SA, Australia. 3. Department of Urology Westmead Hospital, Westmead, NSW, Australia. 4. Alfred Health Radiation Oncology, Melbourne, Vic, Australia. 5. Department of Radiation Oncology, Princess Alexandra Hospital, Wooloongabba, Qld, Australia. 6. WP Holman Clinic, Launceston, Tas., Australia.
Abstract
OBJECTIVES: To establish a Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ) for monitoring outcomes of prostate cancer treatment and care, in a cost-effective manner. MATERIALS AND METHODS: Stakeholders were recruited based on their interest, importance in achieving the monitoring and reporting of clinical practice and patient outcomes, and in amalgamation of existing registries. Each participating jurisdiction is responsible for local governance, site recruitment, data collection, and data transfer into the PCOR-ANZ. To establish each local registry, hospitals and clinicians within a jurisdiction were approached to voluntarily contribute to the registry following relevant ethical approval. Patient contact occurs following notification of prostate cancer through a hospital or pathology report, or from a cancer registry. Patient registration is based on an opt-out model. The PCOR-ANZ is a secure web-based registry adhering to ISO 27001 standards. Based on a standardised minimum data set, information on demographics, diagnosis, treatment, outcomes, and patient reported quality of life, are collected. RESULTS: Eight of nine jurisdictions have agreed to contribute to the PCOR-ANZ. Each jurisdiction has commenced implementation of necessary infrastructure to support rapid rollout. PCOR-ANZ has defined a minimum data set for collection, to enable analysis of key quality indicators that will aid in assessing clinical practice and patient focused outcomes. CONCLUSION: PCOR-ANZ will provide a useful resource of risk-adjusted evidence-based data to clinicians, hospitals, and decision makers on prostate cancer clinical practice.
OBJECTIVES: To establish a Prostate Cancer Outcomes Registry-Australia and New Zealand (PCOR-ANZ) for monitoring outcomes of prostate cancer treatment and care, in a cost-effective manner. MATERIALS AND METHODS: Stakeholders were recruited based on their interest, importance in achieving the monitoring and reporting of clinical practice and patient outcomes, and in amalgamation of existing registries. Each participating jurisdiction is responsible for local governance, site recruitment, data collection, and data transfer into the PCOR-ANZ. To establish each local registry, hospitals and clinicians within a jurisdiction were approached to voluntarily contribute to the registry following relevant ethical approval. Patient contact occurs following notification of prostate cancer through a hospital or pathology report, or from a cancer registry. Patient registration is based on an opt-out model. The PCOR-ANZ is a secure web-based registry adhering to ISO 27001 standards. Based on a standardised minimum data set, information on demographics, diagnosis, treatment, outcomes, and patient reported quality of life, are collected. RESULTS: Eight of nine jurisdictions have agreed to contribute to the PCOR-ANZ. Each jurisdiction has commenced implementation of necessary infrastructure to support rapid rollout. PCOR-ANZ has defined a minimum data set for collection, to enable analysis of key quality indicators that will aid in assessing clinical practice and patient focused outcomes. CONCLUSION: PCOR-ANZ will provide a useful resource of risk-adjusted evidence-based data to clinicians, hospitals, and decision makers on prostate cancer clinical practice.
Authors: Abbas Basiri; Jean Jmch de la Rosette; Shahin Tabatabaei; Henry H Woo; M Pilar Laguna; Hamidreza Shemshaki Journal: World J Urol Date: 2018-01-23 Impact factor: 4.226
Authors: M E O'Callaghan; E Raymond; J Campbell; A D Vincent; K Beckmann; D Roder; S Evans; J McNeil; J Millar; J Zalcberg; M Borg; K Moretti Journal: Prostate Cancer Prostatic Dis Date: 2017-06-06 Impact factor: 5.554
Authors: Udit Singhal; Ted A Skolarus; John L Gore; Matthew G Parry; Ronald C Chen; Julie Nossiter; Alan Paniagua-Cruz; Arvin K George; Paul Cathcart; Jan van der Meulen; Daniela A Wittmann Journal: Nat Rev Urol Date: 2022-03-08 Impact factor: 16.430
Authors: Elspeth Raymond; Michael E O'Callaghan; Jared Campbell; Andrew D Vincent; Kerri Beckmann; David Roder; Sue Evans; John McNeil; Jeremy Millar; John Zalcberg; Martin Borg; Kim Moretti Journal: Radiat Oncol Date: 2017-03-21 Impact factor: 3.481
Authors: Cristian Udovicich; Marlon Perera; Michael S Hofman; Shankar Siva; Andres Del Rio; Declan G Murphy; Nathan Lawrentschuk Journal: Prostate Int Date: 2017-02-24
Authors: Wee Loon Ong; Isaac Thangasamy; Declan Murphy; Elizabeth Pritchard; Susan Evans; Jeremy Millar; Venu Chalasani; Prem Rashid; Matthew Winter; Ian Vela; David Pryor; Stephen Mark; Nathan Lawrentschuk Journal: BJU Int Date: 2022-02-21 Impact factor: 5.969
Authors: David I Pryor; Jarad M Martin; Jeremy L Millar; Heather Day; Wee Loon Ong; Marketa Skala; Liesel M FitzGerald; Benjamin Hindson; Braden Higgs; Michael E O'Callaghan; Farhan Syed; Amy J Hayden; Sandra L Turner; Nathan Papa Journal: JAMA Netw Open Date: 2021-11-01